Immunomodulatory Effects Of Tyrosine Kinase Inhibitors (Tkis) In Renal Cell Carcinoma (Rcc) Patients.

e14506Background: RCC is considered a highly immunogenic tumor responding to anti-angiogenetic TKI and immunotherapy. A better understanding of the functions of immune cells in RCC, the immune-modulatory effects of TKIs treatment as well as defining patients most likely to benefit to the different therapies will be crucial to optimize combined or sequential immunotherapeutic approaches in RCC patients. Methods: Monocyte derived Dendritic Cells (DCs) from 10 healthy donors were differentiated in presence of Pazopanib and Sunitinib used at plasmatic equivalent concentration (Sigma-Aldricht). At the end of the culture, DCs were characterized for marker expression, endocytosis, signal transduction and microvesicle release. Similarly, DCs derived from RCC patients were analyzed together with circulating T cells before and during TKI treatments. Results: Pazopanib and Sunitinib differently affect DC differentiation. Pazopanib, but not Sunitinib, strongly improves DC performance as antigen-presenting cells, prom...